Magazine article Drug Topics

Sharp Turn

Magazine article Drug Topics

Sharp Turn

Article excerpt

A federal panel revises treatment guidelines for HIV-infected adults and adolescents

The "hit early, hit hard" approach toward HIV/AIDS treatment is suddenly changing course. The Department of Health & Human Services, in a joint effort with the Henry J. Kaiser Foundation, has released newly revised guidelines with a more conservative approach for treating asymptomatic HIVinfected adults and adolescents. The guidelines continue to recommend antiretroviral therapy for all patients with acute HIV syndrome, those within six months of HIV seroconversion, and all patients with symptoms attributed to HIV infection.

The new approach for when to initiate anti-HIV therapy comes in response to the growing concern that prolonged use of antiretroviral "drug cocktails" can cause potentially dangerous adverse effects and lead to drug resistance. But will these new guidelines prompt overreaction from both patients and physicians, causing patients to discontinue their medications and physicians to adopt a wait-and-see approach that may prove perilous? "I am very concerned that there might be an overreaction, saying that it's the right thing to delay [treatment]," said Charles Farthing, M.D., medical director of AIDS Healthcare Foundation, Los Angeles. "It isn't really [right to delay], it's just the practical thing to do in many cases and remains a complex issue."

The guidelines, which were constructed as a "living document" and are updated by the panel as new data emerge, include recommendations for antiretroviral therapy, including when to start treatment, what drugs to initiate, when to change therapy, and therapeutic options when changing therapy. The latest guidelines recommend starting antiretroviral therapy when an asymptomatic HIVinfected person's CD4 cell count falls below 350 (previously it was 500) or HIV RNA levels are above 30,000 copies/ml (previously it was above 20,000 copies/ml).

The conservative approach is based on the recognition that the restoration of immunologic function still occurs in most patients who start therapy with CD4 cell counts in the 200-350 range, and that toxicities and adherence challenges may outweigh the benefits at CD4 cell counts higher than 350. A major dilemma confronting patients and practitioners is that the available antiretroviral regimens with the greatest potency in terms of viral suppression and CD4 cell preservation are medically complex, are associated with several adverse effects and drug interactions, and pose a substantial challenge for adherence. "What we have seen in the past

five years is ever-increasing survival times in HIV patients, which is the good news. But it comes with the concern that we now need to balance long-term survival and long-term medication [use] with the possibility of long-term complications," said Benjamin Young, M.D., Ph.D., a specialist in HIV resistance with Rose Medical Center, University of Colorado Health Science Center, Denver. Young noted that it becomes more important than ever to weigh the collective risks versus benefits and take a balanced, thoughtful approach toward treating each patient. As the recommendations evolve, patients who have begun highly active therapy at CD4 cell counts greater than 350 may wish to discontinue treatment. It should be noted that there are no clinical data addressing whether this should be done or can be accomplished safely, which highlights the need for an individualized approach to treatment. The table below summarizes some of the risks and benefits associated with delaying therapy. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.